#BEGIN_DRUGCARD DB01422

# AHFS_Codes:
Not Available

# ATC_Codes:
J01XX07

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Galinok
Isinok
Nicene forte
Noxibiol
Noxin

# CAS_Registry_Number:
4008-48-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H6N2O3

# Chemical_IUPAC_Name:
5-nitroquinolin-8-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2007-07-24 05:15:42 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a fluorquinolone that is active against bacterial gyrases.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents, Urinary
Antifungal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.99

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nitroxoline

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H

# InChI_Key:
InChIKey=RJIWZDNTCBHXAL-UHFFFAOYSA-N

# Indication:
Nitroxoline is an antibiotic agent.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1422

# Mechanism_Of_Action:
This drug may also have antitumor activity by inhibition of ype 2 methionine aminopeptidase (MetAP2) protein which is involved in angiogenesis. Its antibacterial activity may stem from the metal ion complexation vital for bacterial growth.

# Melting_Point:
180 Â°C

# Molecular_Weight_Avg:
190.1555

# Molecular_Weight_Mono:
190.037842068

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164754993

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.9

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
2.73e+00 g/l

# Primary_Accession_No:
DB01422

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
19910

# PubChem_Substance_ID:
46505497

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
5-NOK
5-Nitroks
5-Nitrox
5-Nitroxine
Nitroxolina [inn-spanish]
Nitroxolinum [inn-latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:09 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitroxoline

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
4

# Drug_Target_1_Drug_References:
21088277	Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO: Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2010 Dec 15;102(24):1855-73. Epub 2010 Nov 18.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D42084

# Drug_Target_1_GenBank_ID_Protein:
577315

# Drug_Target_1_GeneCard_ID:
METAP1

# Drug_Target_1_Gene_Name:
METAP1

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15592455	Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005 Jan;23(1):94-101. Epub 2004 Dec 12.
16274222	Addlagatta A, Hu X, Liu JO, Matthews BW: Structural basis for the functional differences between type I and type II human methionine aminopeptidases. Biochemistry. 2005 Nov 15;44(45):14741-9.
16724298	Hu X, Addlagatta A, Matthews BW, Liu JO: Identification of pyridinylpyrimidines as inhibitors of human methionine aminopeptidases. Angew Chem Int Ed Engl. 2006 Jun 2;45(23):3772-5.
16823043	Addlagatta A, Matthews BW: Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase. Protein Sci. 2006 Aug;15(8):1842-8. Epub 2006 Jul 5.
17114291	Hu X, Addlagatta A, Lu J, Matthews BW, Liu JO: Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18148-53. Epub 2006 Nov 17.
7788527	Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H, et al.: Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1995;2(1):37-43.

# Drug_Target_1_HGNC_ID:
GNC:15789

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6621

# Drug_Target_1_Locus:
4q23

# Drug_Target_1_Molecular_Weight:
43214.9

# Drug_Target_1_Name:
Methionine aminopeptidase 1

# Drug_Target_1_Number_of_Residues:
386

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00557	Peptidase_M24

# Drug_Target_1_Protein_Sequence:
>Methionine aminopeptidase 1
MAAVETRVCETDGCSSEAKLQCPTCIKLGIQGSYFCSQECFKGSWATHKLLHKKAKDEKA
KREVSSWTVEGDINTDPWAGYRYTGKLRPHYPLMPTRPVPSYIQRPDYADHPLGMSESEQ
ALKGTSQIKLLSSEDIEGMRLVCRLAREVLDVAAGMIKPGVTTEEIDHAVHLACIARNCY
PSPLNYYNFPKSCCTSVNEVICHGIPDRRPLQEGDIVNVDITLYRNGYHGDLNETFFVGE
VDDGARKLVQTTYECLMQAIDAVKPGVRYRELGNIIQKHAQANGFSVVRSYCGHGIHKLF
HTAPNVPHYAKNKAVGVMKSGHVFTIEPMICEGGWQDETWPDGWTAVTRDGKRSAQFEHT
LLVTDTGCEILTRRLDSARPHFMSQF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Removes the amino-terminal methionine from nascent proteins. Required for normal progression through the cell cycle

# Drug_Target_1_SwissProt_ID:
P53582

# Drug_Target_1_SwissProt_Name:
AMPM1_HUMAN

# Drug_Target_1_Synonyms:
MAP 1
MetAP 1
Peptidase M 1

# Drug_Target_1_Theoretical_pI:
7.18

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
7793877	Pelletier C, Prognon P, Bourlioux P: Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother. 1995 Mar;39(3):707-13.
7824304	Pelletier C, Prognon P, Latrache H, Villart L, Bourlioux P: [Microbiological consequences of chelation of bivalent metal cations by nitroxoline]. Pathol Biol (Paris). 1994 May;42(5):406-11.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7210

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Magnesium

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
7793877	Pelletier C, Prognon P, Bourlioux P: Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother. 1995 Mar;39(3):707-13.
7824304	Pelletier C, Prognon P, Latrache H, Villart L, Bourlioux P: [Microbiological consequences of chelation of bivalent metal cations by nitroxoline]. Pathol Biol (Paris). 1994 May;42(5):406-11.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
Not Available

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
7211

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
manganese

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Not Available

# Drug_Target_3_SwissProt_Name:
Not Available

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB01422
